comparemela.com

Oleg Gluz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Endocrine Therapy Response Status Is Necessary for Treatment Planning in HR+/HER2– Early Breast Cancer

Beyond genomic testing, endocrine therapy response should be used to determine whether patients with hormone receptor–positive, HER2-negative, N0-1 early breast cancer.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.